BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 15548915)

  • 21. Spasmodic dysphonia: botulinum toxin injection after recurrent nerve surgery.
    Ludlow CL; Naunton RF; Fujita M; Sedory SE
    Otolaryngol Head Neck Surg; 1990 Feb; 102(2):122-31. PubMed ID: 2113236
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Botulinum toxin therapy of laryngeal muscle hyperactivity syndromes: comparing different botulinum toxin preparations.
    Truong DD; Bhidayasiri R
    Eur J Neurol; 2006 Feb; 13 Suppl 1():36-41. PubMed ID: 16417596
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Laryngeal dystonia (spasmodic dysphonia): observations of 901 patients and treatment with botulinum toxin.
    Brin MF; Blitzer A; Stewart C
    Adv Neurol; 1998; 78():237-52. PubMed ID: 9750921
    [No Abstract]   [Full Text] [Related]  

  • 24. Laryngeal electromyography in movement disorders: preliminary data.
    Kimaid PA; Quagliato EM; Crespo AN; Wolf A; Viana MA; Resende LA
    Arq Neuropsiquiatr; 2004 Sep; 62(3A):741-4. PubMed ID: 15334243
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Indications for botulinum toxin in laryngectomy].
    Klap P; Marion MH; Perrin A; Fresnel-Elbaz E; Cohen M
    Rev Laryngol Otol Rhinol (Bord); 1993; 114(4):281-7. PubMed ID: 8029549
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients.
    Blitzer A; Brin MF; Stewart CF
    Laryngoscope; 1998 Oct; 108(10):1435-41. PubMed ID: 9778279
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term therapy for spasmodic dysphonia: acoustic and aerodynamic outcomes.
    Mehta RP; Goldman SN; Orloff LA
    Arch Otolaryngol Head Neck Surg; 2001 Apr; 127(4):393-9. PubMed ID: 11296047
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of Botulinum Toxin in Spasmodic Dysphonia: A Review of Recent Studies.
    Khan HA
    Cureus; 2023 Jan; 15(1):e33486. PubMed ID: 36628391
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Histology of nerves and muscles in adductor spasmodic dysphonia.
    Chhetri DK; Blumin JH; Vinters HV; Berke GS
    Ann Otol Rhinol Laryngol; 2003 Apr; 112(4):334-41. PubMed ID: 12731628
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of the interarytenoid muscle with botulinum toxin for laryngeal dystonia.
    Hillel AD; Maronian NC; Waugh PF; Robinson L; Klotz DA
    Ann Otol Rhinol Laryngol; 2004 May; 113(5):341-8. PubMed ID: 15174759
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Botulinum toxin injections for the treatment of spasmodic dysphonia.
    Watts CC; Whurr R; Nye C
    Cochrane Database Syst Rev; 2004; 2004(3):CD004327. PubMed ID: 15266530
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Botulinum toxin management of adductor spasmodic dysphonia after failed recurrent laryngeal nerve section.
    Sulica L; Blitzer A; Brin MF; Stewart CF
    Ann Otol Rhinol Laryngol; 2003 Jun; 112(6):499-505. PubMed ID: 12834116
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcomes of botulinum toxin treatment for patients with spasmodic dysphonia.
    Benninger MS; Gardner G; Grywalski C
    Arch Otolaryngol Head Neck Surg; 2001 Sep; 127(9):1083-5. PubMed ID: 11556856
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia.
    Troung DD; Rontal M; Rolnick M; Aronson AE; Mistura K
    Laryngoscope; 1991 Jun; 101(6 Pt 1):630-4. PubMed ID: 2041443
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The impact of long-term botulinum toxin injections on symptom severity in patients with spasmodic dysphonia.
    Damrose JF; Goldman SN; Groessl EJ; Orloff LA
    J Voice; 2004 Sep; 18(3):415-22. PubMed ID: 15331116
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evidence for the effectiveness of botulinum toxin for spasmodic dysphonia from high-quality research designs.
    Watts CR; Truong DD; Nye C
    J Neural Transm (Vienna); 2008; 115(4):625-30. PubMed ID: 17564757
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Longitudinal effects of botulinum toxin injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia.
    Hogikyan ND; Wodchis WP; Spak C; Kileny PR
    J Voice; 2001 Dec; 15(4):576-86. PubMed ID: 11792036
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Botulinum toxin. A new therapeutic alternative in spastic dysphonia (laryngeal abductor dystonia)].
    Loven JO; Brøndbo K; Ganes T
    Tidsskr Nor Laegeforen; 1993 Mar; 113(7):841-3. PubMed ID: 8480289
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of botulinum toxin type A injections on aerodynamic measures of spasmodic dysphonia.
    Adams SG; Durkin LC; Irish JC; Wong DL; Hunt EJ
    Laryngoscope; 1996 Mar; 106(3 Pt 1):296-300. PubMed ID: 8614192
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of botulinum toxin therapy in patients with adductor spasmodic dysphonia: acoustic, aerodynamic, and videoendoscopic findings.
    Zwirner P; Murry T; Swenson M; Woodson GE
    Laryngoscope; 1992 Apr; 102(4):400-6. PubMed ID: 1556889
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.